Insulet Statistics
Total Valuation
Insulet has a market cap or net worth of $12.12 billion. The enterprise value is $12.41 billion.
| Market Cap | 12.12B |
| Enterprise Value | 12.41B |
Important Dates
The next confirmed earnings date is Wednesday, May 6, 2026, before market open.
| Earnings Date | May 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Insulet has 69.26 million shares outstanding. The number of shares has decreased by -2.71% in one year.
| Current Share Class | 69.26M |
| Shares Outstanding | 69.26M |
| Shares Change (YoY) | -2.71% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 0.29% |
| Owned by Institutions (%) | 104.18% |
| Float | 68.97M |
Valuation Ratios
The trailing PE ratio is 50.31 and the forward PE ratio is 27.58. Insulet's PEG ratio is 1.02.
| PE Ratio | 50.31 |
| Forward PE | 27.58 |
| PS Ratio | 4.48 |
| Forward PS | 3.60 |
| PB Ratio | 8.13 |
| P/TBV Ratio | 9.00 |
| P/FCF Ratio | 32.10 |
| P/OCF Ratio | 21.30 |
| PEG Ratio | 1.02 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 22.00, with an EV/FCF ratio of 32.86.
| EV / Earnings | 50.22 |
| EV / Sales | 4.58 |
| EV / EBITDA | 22.00 |
| EV / EBIT | 26.19 |
| EV / FCF | 32.86 |
Financial Position
The company has a current ratio of 2.81, with a Debt / Equity ratio of 0.66.
| Current Ratio | 2.81 |
| Quick Ratio | 1.81 |
| Debt / Equity | 0.66 |
| Debt / EBITDA | 1.74 |
| Debt / FCF | 2.65 |
| Interest Coverage | 7.98 |
Financial Efficiency
Return on equity (ROE) is 18.12% and return on invested capital (ROIC) is 19.68%.
| Return on Equity (ROE) | 18.12% |
| Return on Assets (ROA) | 9.43% |
| Return on Invested Capital (ROIC) | 19.68% |
| Return on Capital Employed (ROCE) | 18.87% |
| Weighted Average Cost of Capital (WACC) | 10.33% |
| Revenue Per Employee | $501,500 |
| Profits Per Employee | $45,759 |
| Employee Count | 5,400 |
| Asset Turnover | 0.86 |
| Inventory Turnover | 1.74 |
Taxes
In the past 12 months, Insulet has paid $92.40 million in taxes.
| Income Tax | 92.40M |
| Effective Tax Rate | 27.22% |
Stock Price Statistics
The stock price has decreased by -30.62% in the last 52 weeks. The beta is 1.20, so Insulet's price volatility has been higher than the market average.
| Beta (5Y) | 1.20 |
| 52-Week Price Change | -30.62% |
| 50-Day Moving Average | 215.79 |
| 200-Day Moving Average | 282.05 |
| Relative Strength Index (RSI) | 32.09 |
| Average Volume (20 Days) | 1,092,658 |
Short Selling Information
The latest short interest is 2.70 million, so 3.90% of the outstanding shares have been sold short.
| Short Interest | 2.70M |
| Short Previous Month | 3.05M |
| Short % of Shares Out | 3.90% |
| Short % of Float | 3.92% |
| Short Ratio (days to cover) | 3.10 |
Income Statement
In the last 12 months, Insulet had revenue of $2.71 billion and earned $247.10 million in profits. Earnings per share was $3.48.
| Revenue | 2.71B |
| Gross Profit | 1.94B |
| Operating Income | 473.80M |
| Pretax Income | 339.50M |
| Net Income | 247.10M |
| EBITDA | 564.20M |
| EBIT | 473.80M |
| Earnings Per Share (EPS) | $3.48 |
Balance Sheet
The company has $716.10 million in cash and $1.00 billion in debt, with a net cash position of -$286.60 million or -$4.14 per share.
| Cash & Cash Equivalents | 716.10M |
| Total Debt | 1.00B |
| Net Cash | -286.60M |
| Net Cash Per Share | -$4.14 |
| Equity (Book Value) | 1.52B |
| Book Value Per Share | 21.53 |
| Working Capital | 1.23B |
Cash Flow
In the last 12 months, operating cash flow was $569.30 million and capital expenditures -$191.60 million, giving a free cash flow of $377.70 million.
| Operating Cash Flow | 569.30M |
| Capital Expenditures | -191.60M |
| Depreciation & Amortization | 90.40M |
| Net Borrowing | -708.10M |
| Free Cash Flow | 377.70M |
| FCF Per Share | $5.45 |
Margins
Gross margin is 71.63%, with operating and profit margins of 17.50% and 9.12%.
| Gross Margin | 71.63% |
| Operating Margin | 17.50% |
| Pretax Margin | 12.54% |
| Profit Margin | 9.12% |
| EBITDA Margin | 20.83% |
| EBIT Margin | 17.50% |
| FCF Margin | 13.95% |
Dividends & Yields
Insulet does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 2.71% |
| Shareholder Yield | 2.71% |
| Earnings Yield | 2.04% |
| FCF Yield | 3.12% |
Analyst Forecast
The average price target for Insulet is $341.48, which is 95.09% higher than the current price. The consensus rating is "Buy".
| Price Target | $341.48 |
| Price Target Difference | 95.09% |
| Analyst Consensus | Buy |
| Analyst Count | 21 |
| Revenue Growth Forecast (5Y) | 13.46% |
| EPS Growth Forecast (5Y) | 22.41% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Insulet has an Altman Z-Score of 9.4 and a Piotroski F-Score of 7.
| Altman Z-Score | 9.4 |
| Piotroski F-Score | 7 |